Skip to main content

Table 2 Clinical characteristics of patients with primary cervical lymphoma (N = 177)

From: Advanced Ann Arbor stage and age over 60 years as prognostic predictors in patients with primary cervical lymphoma: a retrospective cohort study and systematic review

Clinical characteristics

Number (Percentile)

Age (Mean/Median, y)

48.9 ± 15.8/49.0 (20–85)

Time of follow-up (Mean/Median, y)

4.2/2.9 (0.08–20.50)

Maximum Tumor size (N = 106)

6.9 ± 3.1 (0.5–18.0)

Elevated LDH (N = 28)

16 (57.1%)

B symptoms

12 (6.8%)

Ann Arbor Stage

 IE

113 (63.8%)

 IIE

41 (23.2%)

 IIIE

4 (2.3%)

 IVE

19 (10.7%)

Pathological subtypes

 DLBCL

113 (63.8%)

 Follicular lymphoma

14 (7.9%)

 NK/T-cell lymphoma

3 (1.7%)

 Burkitt lymphoma

1 (0.6%)

 MALT lymphoma

4 (2.3%)

 B-cell NHL, unspecified

14 (7.9%)

 Other NHL, unspecified

25 (14.1%)

 Hodgkin lymphoma, unspecified

3 (1.7%)

Cancer-directed surgery

59 (33.3%)

Chemotherapy/Radiotherapy details

 No chemotherapy or radiotherapy

12 (6.8%)

 Chemotherapy alone

77 (43.5%)

 Radiotherapy alone

31 (17.5%)

 Radiotherapy + chemotherapy

57 (32.2%)

 With Rituximab

39 (22.0%)

 CHOP/CHOP-like chemotherapy (N = 134)

104 (77.6%)

Clinical outcomes

 No evidence of disease

143 (80.8%)

 Alive with disease

10 (5.7%)

 Die of the disease

19 (10.7%)

 Die of the other disease

5 (2.8%)

  1. Abbreviations: LDH lactate dehydrogenase, DLBCL diffuse large B-cell lymphoma, MALT Mucosa Associated Lymphoid Tissue, NHL Non-Hodgkin lymphoma, CHOP cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone